stride semaglutide 🔴The trial! 👟⤵️ 🔹The STRIDE trial demonstrated that significantly improves function, symptoms, and health-related QoL in patients with symptomatic #cvPAD and T2DM American - The STRIDE trial

This compounds human safety data is limited to short-term GI trial populations and cannot be extrapolated to sustained subcutaneous administration in healthy adults

(2010) The brain RAS and Alzheimers disease

It is classified as a growth hormone secretagogue, meaning it encourages the body to produce more growth hormone naturally

Tirzepatide affects blood sugar through both GLP-1 and GIP pathways, which can produce different glycemic patterns than semaglutide alone

GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled